Febuxostat

Febuxostat
Clinical data
Trade names	Uloric, Adenuric, others
AHFS/Drugs.com	Monograph
MedlinePlus	a609020
License data	US DailyMed: Febuxostat;
Pregnancy; category	AU: B1;
Routes of; administration	By mouth
ATC code	M04AA03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only <;
Pharmacokinetic data
Bioavailability	≥84% absorbed
Protein binding	99.2% to albumin
Metabolism	via CYP1A1, 1A2, 2C8, 2C9, UGT1A1, 1A8, 1A9
Elimination half-life	~5–8 hours
Excretion	Urine (~49%, mostly as metabolites, 3% as unchanged drug); feces (~45%, mostly as metabolites, 12% as unchanged drug)
Identifiers
	IUPAC name 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-; 1,3-thiazole-5-carboxylic acid;
CAS Number	144060-53-7 ;
PubChem CID	134018;
IUPHAR/BPS	6817;
DrugBank	DB04854 ;
ChemSpider	118173 ;
UNII	101V0R1N2E;
KEGG	D01206 ;
ChEBI	CHEBI:31596;
ChEMBL	ChEMBL1164729 ;
CompTox Dashboard (EPA)	DTXSID8048650 ;
ECHA InfoCard	100.207.329
Chemical and physical data
Formula	C16H16N2O3S
Molar mass	316.38 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N#Cc1c(OCC(C)C)ccc(c1)c2nc(c(s2)C(=O)O)C;
	InChI InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20) ; Key:BQSJTQLCZDPROO-UHFFFAOYSA-N ;
	(what is this?) (verify)

Febuxostat, sold under the brand name Uloric among others, is a medication used long-term to treat gout due to high uric acid levels. It is generally recommended only for people who cannot take allopurinol. It is taken by mouth.

Common side effects include liver problems, nausea, joint pain, and a rash. Serious side effects include an increased risk of death as compared with allopurinol, Stevens–Johnson syndrome, and anaphylaxis. Use is not recommended during pregnancy or breastfeeding. It inhibits xanthine oxidase, thus reducing production of uric acid in the body.

Febuxostat was approved for medical use in the European Union in 2008, and in the United States in 2009. A generic version was approved in 2019.